Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)

NCT04524455 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04524455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04524455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-label Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Administration of Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
October 2, 2020
Completion date
January 24, 2023
Enrollment
17 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia